Although the global capacity remains small, the potential is enormous and solar power is expected to contribute significantly to electricity production by the middle of the century.

Solar thermal power generation depends on both a high solar intensity and a large amount of direct incident radiation not scattered by clouds. The best sites are generally in arid, desert regions with high annual sunshine levels. Most of these sites are found between 15º and 40º of latitude either side of the equator.

Scope of this research

• Realize up-to-date competitive intelligence through a comprehensive review of concentrating solar power technologies concepts in power generation.
• Assess the emerging trends in csp technologies – parabolic troughs, solar towers, parabolic dishs, Fresnel reflectors and energy storage.
• Identify which key trends will offer the greatest growth potential and learn which technology trends are likely to have greater market impact.
• Compare how manufacturers are developing new concentrating solar power technologies.
• Quantify costs of csp technologies, with comparisons against other forms of power generation technology, installation costs, cost of electricity.

Research and analysis highlights

While the recent growth in output is promising, solar thermal power plants still provide only a tiny fraction of global power consumption. Total global electricity production in 2008 was 20,169,000GWh. Of this renewable production (mostly from hydropower) accounted for 18.7% and the solar thermal contribution was 0.005%.

The average energy density reaching the earth’s surface is about 170W/m3 and the greatest, in the region of the Red Sea, is close to 300W/m3.

Across the region encompassing Africa, southern Europe and Asia, there is potential to generate 7,350TWh/y while the Pacific region could provide a further 2,300TWh/y.

Key reasons to purchase this research

• What are the drivers shaping and influencing concentrating solar power technology development in the electricity industry?
• What does concentrating solar power generation cost? What will it cost in the future?
• Which concentrating solar power technology types will be the winners and which the losers in terms of power generated, cost and viability?
• Which concentrating solar power technology types are likely to find favor with manufacturers moving forward?
• Which emerging technologies are gaining in popularity and why?

To know more about this report & to buy a copy please visit:
http://www.visionshopsters.com/product/12846/The-Future-of-Concentrating-Solar-Power-Technologies.html

Climate change is now central to many national and international political and legislative agendas: businesses must take this into account in planning strategically.

This report is a summary of and a response to that rapidly changing picture. It takes account of recent events, including the failed international initiative at Copenhagen in 2009: and it proposes a framework and approach for businesses seeking to get this issue right, without tying themselves down with open-ended spending obligations.

Scope of this research
• Newly developed framework tool enabling companies to evaluate their own corporate social responsibility achievements
• Overview of political and legislative tools available to governments seeking to regulate corporate energy use
• Recommendations for future policy: balancing consumer demand, regulatory pressure and business need
• Principles of brand and marketing in a world attuned to corporate social responsibility
• Case studies covering corporate initiatives by business sector and by business focus

Research and analysis highlights

Climate change is now central to many national and international political and legislative agendas: businesses must take this into account in planning strategically.

Consumer response to climate change is far less homogenous than believed: in addition to being inconsistent and ill-informed, there is a distinct consumer segment that actively resists business “over-reaction” in this area, penalising those businesses believed to be adding cost unnecessarily through csr programmes.

Business solutions need to take account of the fact that their CO2 emissions are the result of complex interactions between inter-locking areas in business: change needs to be considered holistically (to ensure that improvement in one area is not wiped out by worse performance in another).

Key reasons to purchase this research
• What are the key issues driving the development of corporate social responsibility initiatives?
• How can business evaluate their own performance in this area? Where can they go for assistance?
• What is the downside to CSR, both in terms of failure to adapt (under-performance) and taking it up too enthusiastically (over-delivery)?
• What are some of the key areas where businesses need to review their CSR performance?
• What are the “quick win” areas? Review of consumer attitudes in the area of environmental friendliness

To know more about this report & to buy a copy please visit:
http://www.visionshopsters.com/product/16207/Corporate-Carbon-Strategies-Threats-and-opportunities-arising-from-the-new-energy-imperative.html

Energy Companies of the Arab World 2010 covers hundreds of companies in the Middle East and North Africa involved in electrical and power generation; fuel distribution; natural gas supply; oil and gas exploration and production; and oil and gas services.

Entries typically provide: company name; address; telephone, and fax numbers; names of senior management and board members, including senior executives; description of business activities; and subsidiaries and associates.

The Directory includes a comprehensive index and an index listing company names alphabetically by country.

This Directory will be useful in businesses that deal specifically with companies in the oil and gas industries.

Features of this Directory:

• Company name, address, telephone and fax numbers, email and web addresses
• Full description of business activities
• Subsidiaries and associates
• Number of employees
• Principal shareholders and public/private status

This Directory will enable you to:

• Profile a market
• Build new business prospects
• Generate new customers
• Discover who your competitors are
• Make vital contacts
• Save the time, money and effort of doing your own research
• Identify alternative suppliers
• Source up-to-date company information
• Access a wealth of quality information on companies and key personnel.

This Directory has been especially compiled to assist with market research, strategic planning, as well as contacting prospective clients or suppliers. It is also an indispensable guide to the Arab world’s energy companies.

This directory is indexed in three ways to make searching quick and easy. Indexes are listed alphabetically by country, alphabetically by company name and by business activity.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1185/Energy-Companies-of-the-Arab-World-2010.html

Contact us:

Visionshopsters
Ph : 91-22-40583000
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

This profile is the essential source for top-level energy industry data and information. The report provides an overview of each of the key sub-segments of the energy industry in France. It details the market structure, regulatory environment, infrastructure and provides historical and forecasted statistics relating to the supply/demand balance for each of the key sub-segments. It also provides information relating to the crude oil assets (oil fields, refineries, pipelines and storage terminals) in France. The report also analyses the fiscal regime relevant to the crude oil assets in France and compares the investment environment in France with other countries in the region. The profiles of the major companies operating in the crude oil sector in France together with the latest news and deals are also included in the report.

Scope

• Historic and forecast data relating to production, consumption, imports, exports and reserves are provided for each industry sub-segment for the period 1996-2020.
• Historical and forecast data and information for all the major oil fields, refineries, pipelines and storage terminals in France for the period 2000-2013.
• Operator and equity details for major crude oil assets in France.
• Key information relating to market regulations, key energy assets and the key companies operating in the France’s energy industry.
• Detailed information on key fiscal terms (such as rents, bonuses, royalty, cost recovery, profit oil, petroleum and corporate taxes) pertaining the geography is also provided. A sample calculation detailing how fiscal terms apply to a typical asset in the regime is included.
• Information on the top companies in the France including business description, strategic analysis, and financial information. Key companies covered include TOTAL S.A, Exxon Mobil Corporation,
• Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
• Key mergers and acquisitions, partnerships, private equity and venture capital investments, and IPOs.

Reasons to buy

• Gain a strong understanding France’s oil market.
• Facilitate market analysis and forecasting of future industry trends.
• Evaluate the attractiveness of this geography for oil investment in the light of government policies and the fiscal environment.
• Facilitate decision making on the basis of strong historic and forecast production, reserves and capacity data.
• Understand the policies and fiscal terms, and their impact on contractor’s profits from upstream oil assets.
• Assess your competitor’s major crude oil assets and their performance.
• Analyze the latest news and financial deals in the oil sector in France.
• Develop strategies based on the latest operational, financial, and regulatory events.
• Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market.
• Identify and analyze the strengths and weaknesses of the leading companies the French oil market.

Companies Mentioned

Gaz de France
TOTAL S.A.
Exxon Mobil Corporation

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3158/France-Oil-Markets-2010-Investment-Opportunities-Market-Analysis-and-Forecasts-to-2020.html
———————————————-

Medical equipment report offering, “Belgium Patient Monitoring Market Outlook to 2016” provides key market data on the Belgium patient monitoring market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within seven market categories – Multiparameter Patient Monitoring, Remote Patient Monitoring, Patient Monitoring Leads and Electrodes, Non-invasive Blood Pressure Monitors, Neonatal Monitors, Fetal Monitors and Micro-electromechanical Systems. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

• Market size and company share data for seven patient monitoring market categories – Multiparameter Patient Monitoring, Remote Patient Monitoring, Patient Monitoring Leads and Electrodes, Non-invasive Blood Pressure Monitors, Neonatal Monitors, Fetal Monitors and Micro-electromechanical Systems.
• Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within seven market categories. Data from 2002 to 2009, forecast forward for 7 years to 2016.
• 2009 company shares and distribution shares data for each of the seven market categories.
• Global corporate-level profiles of key companies operating within the Belgium patient monitoring market.
• Key players covered include Philips Healthcare, GE Healthcare, Draegerwerk AG & Co. KGaA, OMRON HEALTHCARE Co., Ltd., Nihon Kohden Corporation, Mindray Medical International Limited and Medtronic, Inc.

Reasons to buy

• Develop business strategies by identifying the key market categories and segments poised for strong growth.
• Develop market-entry and market expansion strategies.
• Design competition strategies by identifying who-stands-where in the Belgium patient monitoring competitive landscape.
• Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
• What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Companies Mentioned

Philips Healthcare
GE Healthcare
Draegerwerk AG & Co. KGaA
OMRON HEALTHCARE Co., Ltd.
HARTMANN GROUP
A&D Medical / LifeSource
3M Health Care
Welch Allyn Inc.
The Dixion Company
Terumo Corporation
St. Jude Medical, Inc.
Spacelabs Healthcare, Inc.
Siemens Healthcare
Schiller AG
Rossmax International Ltd.
OSI Systems, Inc.
Nihon Kohden Corporation
Mindray Medical International Limited
Microlife Corporation
Mennen Medical Ltd.
Medtronic, Inc.
Larsen & Toubro Medical Equipment & Systems
GE Sensing & Inspection Technologies
Fukuda Denshi Co., Ltd.
Edwards Lifesciences Corporation
Edan Instruments, Inc.
Criticare Systems, Inc.
Covidien plc
CONMED Corporation
LifeWatch AG
Boston Scientific Corporation
BIOTRONIK SE & Co. KG
Bionet Co.,Ltd.
AViTA Corporation
Ambu A/S
Patient Monitoring Market Pipeline Products

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3143/Belgium-Patient-Monitoring-Market-Outlook-to-2016.html
———————————————-

“Dysmenorrhea – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global dysmenorrhea market. The report identifies the key trends shaping and driving the global dysmenorrhea market. The report also provides insight into the prevalent competitive landscape and the emerging players expected to bring a significant shift in the positioning of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the global dysmenorrhea sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts
The global dysmenorrhea therapeutics market was valued at $1.7 billion in 2009. It is expected to grow at a Compound Annual Growth Rate (CAGR) of 3.9% by 2016. This slow growth is primarily attributed to due to the lack of diagnostic techniques, disease awareness and the poor safety and efficacy profiles of the existing therapies. The current competitive landscape consists of only generics and off-label therapies, none of which have a dominant position. The current emphasis has been on treating the symptoms of the disease without providing an absolute cure.

Scope

The scope of the report includes:
- Annualized global dysmenorrhea market revenues data from 2001 to 2009, forecast forward for seven years to 2016.
- Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.
- Pipeline analysis data providing a split across different phases by the mechanism of action being developed and emerging trends. Key classes of mechanism of action include prostaglandin synthetase inhibitors and COX-2 inhibitors.
- Analysis of the current and future market competition in the global dysmenorrhea market. Key market players covered are China Aoxing Pharmaceutical Company, Vantia Therapeutics, Columbia Laboratories, Merck and Bayer Schering Pharma AG.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessments, market characterization, the unmet needs and the implications for the future market associated with dysmenorrhea.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through a review of the pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global dysmenorrhea market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global dysmenorrhea market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain the competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global dysmenorrhea market landscape? – Identify, understand and capitalize.

Companies Mentioned

China Aoxing Pharmaceutical Co., Inc
Merck
Vantia Therapeutics
Bayer Schering Pharma
Columbia Laboratories

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3104/Dysmenorrhea-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
———————————————-

“Acne – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global acne market. The report identifies the key trends shaping and driving the global acne market. The report also provides insight into the prevalent competitive landscape and the emerging players expected to significantly alter the positioning of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the global acne sector. GlobalData’s research suggests that the global acne market was worth $2.8 billion in 2009. The moderate increase in revenues in the future is attributed to the overcrowding of the market with generics and the increased acceptance of alternative therapies such as photodynamic therapy and UV/blue light therapy. The current market has several products which act on acne by targeting different etiologic factors involved in the development of acne. Solodyn currently rules the acne market, followed by Doryx. The acne therapeutics market is witnessing a shift towards products which are a combination of two or more effective acne treatments. The currently marketed combination products such as Duac and Ziana are forecast to steadily increase their revenues.

Scope

The scope of the report includes:
- Annualized global acne market revenue data from 2001 to 2009, forecast for seven years to 2016.
- Geographies covered in this report are the US, the UK, Italy, Spain, Germany, France and Japan.
- Pipeline analysis data providing a split across the different phases of development by mechanism of action and emerging trends. The key classes of mechanism of action include antimicrobials, combination therapies, antibacterial and anti-inflammatory, enzyme inhibitors, androgen antagonists, oxidizing agents and comedolytic agents.
- Analysis of the current and future market competition in the global acne market. The key market players covered are Steifel laboratories, Allergan, Galderma, & and Cosmo Pharmaceuticals.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future acne market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global acne market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global acne market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global acne market landscape? – Identify, understand and capitalize.

Companies Mentioned

Cosmo Pharmaceuticals
Stiefel, a GSK company
Galderma S.A
Allergan Inc (Allergan)

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3103/Acne-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
———————————————-

“Candidiasis – Drug Pipeline Analysis and Market Forecasts to 2016”, provides an essential source of information and analysis on the global candidiasis market. The report identifies the key trends shaping and driving the global candidiasis market. The report also provides insights on the prevalent competitive landscape and the companies expected to significantly alter the market landscape. Most importantly, the report provides valuable insights on the pipeline products within the global candidiasis sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData forecasts the global candidiasis market to reach $2,386m by 2016. This moderate growth will primarily be supported by an increase in the disease incidence rate and the launch of two promising pipeline molecules during the forecast period. The growth of the candidiasis market during the forecast period will not be much higher than the rate at which it grew between 2001 and 2009. This is primarily attributed to two reasons. First, the candidiasis market is dominated by generic products which generate less revenue per unit volume sold. Second, the pipeline of the candidiasis market is weak with a small number of molecules across different stages of development. However, the continued uptake of the currently marketed products and the launch of some of the late-stage pipeline molecules will sustain market growth during the forecast period.

Scope

The scope of the report includes:
- Annualized global candidiasis market revenues data from 2001 to 2009, forecast for seven years to 2016.
- Geographies covered in this report are the United States (the US), the United Kingdom (the UK), Italy, Spain, Germany, France and Japan.
- Pipeline analysis data providing a split across phases by mechanism of action, and the emerging trends. The key classes of mechanism of action include monoclonal antibodies, cytochrome inhibitors, combination therapies, aminio acid sequences and antimicrobial peptides, selective immune response amplifiers, vaccines and protein synthesis inhibitors.
- Analysis of the current and future market competition in the global candidiasis market. The key market players covered Neutec Pharma PLC (a wholly owned subsidiary of Novartis AG), Novartis AG, Demegen, Inc. and Basilea Pharmaceutica Ltd.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- The key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future candidiasis market.

Reasons to buy

The report will enhance your decision making capability in a rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through a review of the pipeline products and technologies and by identifying the companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global candidiasis market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global candidiasis market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global candidiasis market landscape? – Identify, understand and capitalize.

Companies Mentioned

Neutec Pharma PLC
Novartis AG
Demegen, Inc
Basilea Pharmaceutica Ltd

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3102/Candidiasis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
———————————————-

“Hepatitis B – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global hepatitis B market. The report identifies the key trends shaping and driving the global hepatitis B market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global hepatitis B (Hep B)sector.

GlobalData’s analysis revealed that the market grew at a Compound Annual Growth Rate (CAGR) of 5.9% since 2001 to reach $879m in 2009. Growth in the Hep B market will be driven by the increasing number of patients over the next few years. The current Hep B market is dominated by anti-viral therapies and this trend likely to continue, with no innovative molecules in the developmental pipeline. GlobalData’s analysis showed that the Hep B pipeline is weak in terms of the number of molecules. The pipeline molecules in the Hep B market primarily comprise of me-too molecules (five), and combination therapies (five), with efficacy and safety profiles similar to the present therapeutic options. The most promising molecules among them are combinations of entecavir plus adefovir and tenofovir plus emtricitabine.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:
- Annualized global Hep B market revenues data from 2001 to 2009, forecast forward for seven years to 2016.
- Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.
- Pipeline analysis data providing an overview of different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action are nucleoside/nucleotide anti-virals, glucocorticoids and Natural Killer Ts (NKTs).
- Analysis of the current and future market competition in the global Hep B market. The key market players covered are Bristol-Myers Squibb and Gilead Science Inc.
- Insightful reviews of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessments, market characterization, unmet needs, and the implications for the future market associated with Hep B.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global hepatitis B market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global hepatitis B market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global hepatitis B market landscape? – Identify, understand and capitalize.

Companies Mentioned

Bristol-Myers Squibb
Gilead Sciences, Inc

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3101/Hepatitis-B-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
———————————————-

“Tuberculosis – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global Tuberculosis (TB) drugs market. The report identifies the key trends shaping and driving the global TB market. The report also provides insight into the prevalent competitive landscape and the emerging players expected to significantly alter the positioning of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the global TB sector. The global TB drugs market was worth $99m in 2009. The market is expected to decline by 2.8% during the next seven years. The TB drugs market has been well served by antimycobacterial agents and antibiotics since the 1960s. The cure rates have improved with the conventional DOTs (Directly Observed Therapy). Multi-Drug Resistant Tuberculosis (MDR-TB) has been a consequence of patient non-compliance and the long duration of therapy. Companies seem to be actively developing products for the prophylaxis and cure of TB that have lesser treatment durations. The two not-for-profit organizations, TB Alliance and the Aeras Global TB Vaccine Foundation, have partnered with pharmaceutical players in order to address the burden of TB in developed and developing nations. With the success of the ongoing clinical studies, the market is expected to witness a breakthrough in TB control and treatment. The vaccines’ primary focus would be to inhibit the infection at the first place. The global TB drugs market is heading towards a phase of decline as no launches are expected till 2016.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:
- Annualized global Tuberculosis drugs market revenue data from 2001 to 2009, forecast for seven years to 2016.
- Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.
- Pipeline analysis data providing a split across the different phases of development by mechanism of action and emerging trends. The key classes of mechanism of action of drugs include ATP synthase inhibitors, protein synthesis inhibitors, cell wall synthesis inhibitors, DNA gyrase inhibitors, FAS synthase inhibitors, translocase-1 inhibitors and others. The vaccine candidates have been segmented as recombinant live vaccines, recombinant protein vaccines and viral vectored vaccines.
- Analysis of the current and future market competition in the global Tuberculosis drugs market. The key market players covered are isoniazid, rifampin, pyrazinamide, ethambutol, streptomycin, rifabutin and capreomycin.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessments, market characterization, the unmet needs and the implications for the future market associated with TB.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global tuberculosis market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global tuberculosis market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global tuberculosis market landscape? – Identify, understand and capitalize.

Companies Mentioned

TB Alliance, the US
Aeras (Aeras Global TB Vaccine Foundation), the US
Crucell, the Netherlands
Tibotec BVBA, Belgium

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3100/Tuberculosis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
———————————————-